Merck, Bristol Myers Cancer Drugs Included in September FDA Advisory Panel Meeting
Bristol-Myers Squibb Company's (NYSE:BMY) Latest 3.0% Decline Adds to One-year Losses, Institutional Investors May Consider Drastic Measures
Express News | Bristol-Myers Squibb Says FDA Schedules Oncologic Drugs Advisory Committee Meeting For September 26 To Discuss PD-L1 Expression Levels In Gastric And Esophageal Cancers
Express News | Bristol-Myers Squibb Co - Meeting to Discuss Pd-L1 Expression Levels in Gastric and Esophageal Cancers
Express News | Bristol-Myers Squibb Co - FDA Will Hold a Public Meeting of the Oncologic Drugs Advisory Committee (Odac) on September 26
Express News | Zenas Biopharma Inc Says Bristol-Myers Squibb Co, Xencor Inc Are Among 5% or Greater Stockholders in the Company
Bristol Myers' (BMY) HCC Combo Drug Accepted for FDA Review
Bristol-Myers Squibb Is Maintained at Underweight by Barclays
Bristol-Myers Squibb Analyst Ratings
Barclays Maintains Bristol-Myers Squibb(BMY.US) With Sell Rating, Announces Target Price $42
Barclays Reaffirms Their Sell Rating on Bristol-Myers Squibb (BMY)
Bristol-Myers Squibb's Options Frenzy: What You Need to Know
Jefferies Reaffirms Their Hold Rating on Bristol-Myers Squibb (BMY)
FDA to Review Bristol Myers Opdivo/Yervoy Combo in Liver Cancer
Barclays Adjusts Bristol-Myers Squibb Price Target to $42 From $41, Maintains Underweight Rating
Express News | The FDA Has Accepted Bristol Myers Squibb's Supplemental Biologics License Application For Opdivo (Nivolumab) Plus Yervoy (Ipilimumab) As Potential First-line Treatment For Adult Patients With Unresectable Hepatocellular Carcinoma, With Prescription...
Express News | Bristol-Myers Squibb Co - FDA Assigns Pdufa Goal Date of April 21, 2025
Express News | Bristol-Myers Squibb Co - U.S. Food and Drug Administration Assigned a Target Action Date of April 21, 2025
Express News | Bristol Myers Squibb Receives U.S. Food and Drug Administration Sbla Acceptance for First-Line Treatment of Unresectable Hepatocellular Carcinoma
Kidney Cancer Drugs Global Strategic Business Report 2023-2030 With Focus on Key Players Including Bayer, Bristol-Myers Squibb, Eisai, Exelixis, Novartis, and Pfizer - ResearchAndMarkets.com